- September 17, 2022
- Newsletter
- 617-430-5616
Menu
» Home » CAD » Infectious Disease » Parasitic Infection » African Trypanosomiasis
ADVERTISEMENT
ADVERTISEMENT
» Home » CAD » Infectious Disease » Parasitic Infection » African Trypanosomiasis
Background
Epidemiology
Anatomy
Pathophysiology
Etiology
Genetics
Prognostic Factors
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Investigational Drug:
2 to 3.6mg/kg/day intravenous for three days
After one week, administer 3.6mg/kg/day intravenous for three days
Repetition after 10 to 21 days: 3.6 mg/kg per day
It is used for HAT hemolymphatic stage 1 and meningoencephalitic stage 2
10-Day treatment regimen
Days 1 to 4: 1800 mg (3 tab) orally every day, following
Days 5 to 10: 1200 mg (2 tab) orally every day
Dose Adjustments
Dosage Modifications
Hepatic impairment
pharmacokinetics not known; Contraindicated
Renal impairment
Mild-moderate (eGFR 30 to less than 89 mL/min/1.73 m2): dose adjustment is not required
Severe (eGFR less than 30 mL/min/1.73 m2): Pharmacokinetics are not known; avoid usage
Investigational Drug:
A dose of 18-25 mg/kg is administered once a month
Initial dose: 0.36mg/kg intravenously
Gradually increase to 3.6 mg/kg IV at 1-5 days intervals for a total of 9-10 doses
It is used for HAT hemolymphatic stage 1 and meningoencephalitic stage 2 in children aged above 6 years who weight 20 kg
Below 6 years: Safety & efficacy were not established
Above 6 years
10-Day treatment regimen
Above 20 to less than 35 kg
Days 1 to 4: 1200 mg (2 tab) orally every day, following
Days 5 to 10: 600 mg (1 tab) orally every day
More than 35 kg
Days 1 to 4: 1800 mg (3 tab) orally every day, following
Days 5 to 10: 1200 mg (2 tab) orally every day
Dose Adjustments
Dosage Modifications
Hepatic impairment
pharmacokinetics not known; Contraindicated
Renal impairment
Mild-moderate (eGFR 30 to less than 89 mL/min/1.73 m2): dose adjustment is not required
Severe (eGFR less than 30 mL/min/1.73 m2): Pharmacokinetics are not known; avoid usage
Future Trends
References
ADVERTISEMENT
» Home » CAD » Infectious Disease » Parasitic Infection » African Trypanosomiasis
Investigational Drug:
2 to 3.6mg/kg/day intravenous for three days
After one week, administer 3.6mg/kg/day intravenous for three days
Repetition after 10 to 21 days: 3.6 mg/kg per day
It is used for HAT hemolymphatic stage 1 and meningoencephalitic stage 2
10-Day treatment regimen
Days 1 to 4: 1800 mg (3 tab) orally every day, following
Days 5 to 10: 1200 mg (2 tab) orally every day
Dose Adjustments
Dosage Modifications
Hepatic impairment
pharmacokinetics not known; Contraindicated
Renal impairment
Mild-moderate (eGFR 30 to less than 89 mL/min/1.73 m2): dose adjustment is not required
Severe (eGFR less than 30 mL/min/1.73 m2): Pharmacokinetics are not known; avoid usage
Investigational Drug:
A dose of 18-25 mg/kg is administered once a month
Initial dose: 0.36mg/kg intravenously
Gradually increase to 3.6 mg/kg IV at 1-5 days intervals for a total of 9-10 doses
It is used for HAT hemolymphatic stage 1 and meningoencephalitic stage 2 in children aged above 6 years who weight 20 kg
Below 6 years: Safety & efficacy were not established
Above 6 years
10-Day treatment regimen
Above 20 to less than 35 kg
Days 1 to 4: 1200 mg (2 tab) orally every day, following
Days 5 to 10: 600 mg (1 tab) orally every day
More than 35 kg
Days 1 to 4: 1800 mg (3 tab) orally every day, following
Days 5 to 10: 1200 mg (2 tab) orally every day
Dose Adjustments
Dosage Modifications
Hepatic impairment
pharmacokinetics not known; Contraindicated
Renal impairment
Mild-moderate (eGFR 30 to less than 89 mL/min/1.73 m2): dose adjustment is not required
Severe (eGFR less than 30 mL/min/1.73 m2): Pharmacokinetics are not known; avoid usage
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.